Table 1 |
||||
|
Summary of proteomic approaches used to analyze plasma for breast cancer biomarkers |
||||
| Approaches |
Examples |
Pros |
Cons |
|
|
|
||||
| Nondirected/global |
Identification based |
Tandem MS |
Unbiased searches Protein identities are determined Highly reproducible |
Requires fractionation and/or depletion/enrichment to overcome limited dynamic range Time intensive |
| Pattern based |
MALDI-TOF-MS |
High throughput Potentially applicable for clinical use Unbiased searches |
Protein identities not determined, making validation difficult Identified proteins have been high-abundance immune and clotting factors |
|
| Low reproducibility between laboratories |
||||
| Target specific |
Western/ELISA/antibody arrays |
Relatively high throughput Clinically applicable Identity of proteins is known |
Limited antibody availability Untargeted proteins will remain undetected |
|
|
|
||||
|
ELISA, enzyme-linked immunoisorbent assay; MALDI, matrix-assisted laser desorption/ionization; MS, mass spectrometry; TOF, time-of-flight. |
||||
|
Davis and Hanash Breast Cancer Research 2006 8:217 doi:10.1186/bcr1619 |
||||